Document Detail


Role of the cholinesterase inhibitors in the treatment of schizophrenia.
MedLine Citation:
PMID:  23330829     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
The effects of cognitive impairment on the occupational functioning, social activity, and economic life of patients with schizophrenia constitute major obstacles to recovery. Currently, the standard biological treatment for schizophrenia consists of antipsychotic medications, which results in significant improvements in psychotic symptoms such as delusions and hallucinations via a high affinity for numerous neurotransmitter receptors. However, the effects of antipsychotics on cognitive dysfunction appear very limited or minimal in clinical practice. In fact, according to recent clinical trials, newer antipsychotics, which have little effect on cholinergic receptors but potent antagonistic effects on the serotonin-7 receptor (5-HT(7); e.g., lurasidone), may ameliorate cognitive defects in patients with schizophrenia. It has been consistently reported that both nicotinic and muscarinic receptors play crucial roles in cognition and, thus, that they may be considered potential therapeutic targets for new drugs designed to decrease cognitive deficits. Accordingly, cholinesterase inhibitors (ChEIs) may be effective in enhancing the cognitive functioning of patients with schizophrenia. Not surprisingly, such drugs have been utilized to treat cognitive deficits in patients with schizophrenia in a handful of clinical trials. This paper reviews a brief background information and discusses current clinical issues regarding the use of ChEIs in patients with schizophrenia.
Authors:
Chi-Un Pae
Related Documents :
23609519 - Usefulness of treatment reports for electroconvulsive therapy.
20300729 - Social dynamics of postpartum depression: a population-based screening in south-eastern...
24649359 - Assessing depression in cardiac patients: what measures should be considered?
11605999 - Associations between nonshared environment and child problem behaviour.
23355089 - Organic bases of late-life depression: a critical update.
25132609 - Withdrawn: sleep quality changes in chronically depressed patients treated with mindful...
12023699 - A randomized clinical trial of nebulized magnesium sulfate in addition to albuterol in ...
16239179 - The recognition of stroke in the emergency room (rosier) scale: development and validat...
9695299 - Short-term effects of budesonide, nedocromil sodium and salmeterol on bronchial hyperre...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-1-21
Journal Detail:
Title:  Expert opinion on investigational drugs     Volume:  -     ISSN:  1744-7658     ISO Abbreviation:  Expert Opin Investig Drugs     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-1-21     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9434197     Medline TA:  Expert Opin Investig Drugs     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
The Catholic University of Korea College of Medicine, Bucheon St. Mary's Hospital, Department of Psychiatry , 2 Sosa-Dong, Wonmi-Gu, Pucheon, Kyounggi-Do 420-717 , Republic of Korea ; pae@catholic.ac.kr.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Diffusing Colloidal Probes of Protein-Carbohydrate Interactions.
Next Document:  Racial Disparities in Left Main Stenting: Insights from a Real World Inner City Population.